Three patents currently held, every record listed here
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Jul 2042. from the record
Of the 5 now held by other companies, 5 name Bioclinica Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2042
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2012 to 2044.
US 8,300,910
Pathology Indicating Measure Related to Cartilage Structure and Automatic Quantification Thereof
Apr 29, 2029
US 11,953,500
Detection Reagent and Therapeutic Target for B Cell Tumor After Targeted Therapy and Related Application
Jul 21, 2042
US 12,146,881
Reagent Composition for Detection of Non-Hematopoietic Tumor and Use Thereof
Jun 14, 2043
US 12,492,980
Antibody Combination for One-Step Screening And/Or Diagnosis of Clonal Diseases and Related Application
Jul 20, 2044
20192026203320402044
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Dec 2027 · High confidence
Cited by 35 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Bioclinica, Inc.
Also notable
Ends Nov 2028 · High confidence
The most cited patent in this portfolio, cited by 42 later US patents, top 25% of utility patents granted in 2012 in our data. Protection runs to 2028.
now held by Bioclinica, Inc.
Also notable
Ends Oct 2028 · High confidence
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
now held by Bioclinica, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 9, 2027The maintenance fee for Detection Reagent and Therapeutic Target for B Cell Tumor After Targeted Therapy and Related Application (US 11,953,500) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,953,500 | Detection Reagent and Therapeutic Target for B Cell Tumor After Targeted Therapy and Related Application In force · High confidence | In force | High confidence | |
| US 12,146,881 | Reagent Composition for Detection of Non-Hematopoietic Tumor and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,492,980 | Antibody Combination for One-Step Screening And/Or Diagnosis of Clonal Diseases and Related Application In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 5 patents in force now held by others · 6 patents ended · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed